Accessibility Menu
Nova Eye Medical logo

Nova Eye Medical(ASX) EYE

Market CapA$44.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-37%
5 Year-66%
1 Year+7%
1 Month+35%
A$0.15
-3.23%
-0.01Today
Nova Eye Medical last closing stock price
MetricPriceDate
Last closeAUD 0.162026-08-13
Nova Eye Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.33%AUD 0.152026-08-06
1 month+34.78%AUD 0.122026-07-13
3 month+24%AUD 0.132026-05-15
Year to date+17.42%AUD 0.132025-12-31
1 year+6.9%AUD 0.152025-08-13
3 year-40.38%AUD 0.262023-08-14
5 year-66.3%AUD 0.462021-08-13
Since inception-37.01%AUD 0.251992-01-02

Nova Eye Medical Financials at a Glance

Market Cap

A$44.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$59.16M

Net Income (TTM)

-A$15.59M

EPS (TTM)

-A$0.02

P/E Ratio

-6.22

Dividend

A$0.00

Beta (Volatility)

-0.13 (Low)

Price

A$0.15

Volume

186,626

Open

A$0.16

Previous Close

A$0.16

Daily Range

A$0.15 - A$0.16

52-Week Range

A$0.10 - A$0.21

Estimated Earnings Date

Aug 26, 2026

EYE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nova Eye Medical

Nova Eye Medical Limited is a healthcare company focused on developing and marketing innovative surgical equipment for glaucoma treatment. The company offers a range of products designed to improve patient outcomes and enhance surgical precision in eye care.

Products and Services
  • iTrack: A surgical system that reduces intraocular pressure in glaucoma patients
  • Molteno3: A drainage device for severe glaucoma cases
  • 2RT: A proprietary laser technology for age-related macular degeneration
Growth Outlook
  • Recent quarterly revenue reached AUD 16.7 million, indicating strong market demand
  • Expansion into international markets enhances growth potential
  • Innovative product pipeline supports long-term revenue growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 63.5 million reflects a solid performance
  • Gross profit margin improved to 70.1% in the latest quarter
  • Current ratio of 1.85 indicates strong liquidity position
Nova Eye Medical Limited has established itself as a key player in the medical devices sector, particularly in glaucoma treatment. The company's innovative products, such as iTrack and Molteno3, are designed to address critical needs in eye care, positioning the company for future growth. The recent quarterly revenue of AUD 16.7 million demonstrates robust demand for its offerings, while the improved gross profit margin highlights operational efficiency. With a strong liquidity position, as indicated by a current ratio of 1.85, the company is well-equipped to navigate market challenges and capitalize on growth opportunities. The expansion into international markets further enhances the potential for revenue growth, making Nova Eye Medical Limited an intriguing option for investors interested in the healthcare sector.
AI Generated • Jul 21, 2026

Industry

Healthcare Equipment and Supplies

CEO

Thomas Spurling

Headquarters

Kent Town, SA 5067, AU

EYE Financials

Key Financial Metrics (TTM)

Gross Margin

66.71%

Operating Margin

-15.77%

Net Income Margin

-21.27%

Return on Equity

-40.41%

Return on Capital

-51.16%

Return on Assets

-29.70%

Earnings Yield

-16.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$44.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

284.88M

Volume

186.63K

Avg. Volume

290.32K

Financials (TTM)

Gross Profit

A$41.87M

Operating Income

-A$8.77M

EBITDA

-A$10.63M

Operating Cash Flow

-A$12.16M

Capital Expenditure

-A$452.00K

Free Cash Flow

-A$12.62M

Cash & ST Invst.

A$2.62M

Total Debt

A$4.94M

Nova Eye Medical Performance Analysis

Nova Eye Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 13,378,000N/A
20232023-06-30AUD 17,025,00027.3%
20242024-06-30AUD 23,325,00037.0%
20252025-06-30AUD 29,267,00025.5%
Nova Eye Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3030.1%
Q22024-12-31-2.0%
Q42025-06-3026.4%
Q22025-12-312.3%
Nova Eye Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.05N/A
20232023-06-30AUD -0.1089.1%
20242024-06-30AUD -0.04-54.9%
20252025-06-30AUD -0.04-15.1%
Nova Eye Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3049.5%
Q22024-12-31-62.1%
Q42025-06-3041.3%
Q22025-12-3114.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$16.71M

+64.8%

Gross Profit

A$11.72M

+786.3%

Gross Margin

70.11%

N/A

Market Cap

A$44.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$146.70K

N/A

Employees

301

N/A

Net Income

-A$3.37M

+40.2%

EBITDA

-A$2.36M

+43.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$2.62M

+0.4%

Total Debt

A$4.94M

+306.6%

Accounts Receivable

A$4.10M

+85.8%

Inventory

A$3.50M

-15.3%

Long Term Debt

A$4.29M

+668.2%

Short Term Debt

A$646.00K

-50.8%

Return on Assets

-29.70%

N/A

Return on Invested Capital

-29.00%

N/A

Free Cash Flow

-A$2.41M

+46.1%

Operating Cash Flow

-A$2.28M

+44.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HMD.AXHeraMED Limited
A$0.04+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%
MAP.AXMicroba Life Sciences Limited
A$0.05+0.00%
IIQ.AXINOVIQ Ltd
A$0.20+2.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About EYE

What is the current price of Nova Eye Medical?

Nova Eye Medical is trading at A$0.15 per share.

What is the 52-week range for Nova Eye Medical?

Over the past 52 weeks, Nova Eye Medical has traded between A$0.10 and A$0.21.

How much debt does Nova Eye Medical have?

As of the most recent reporting period, Nova Eye Medical reported total debt of A$3.02M.

How much cash does Nova Eye Medical have on hand?

Nova Eye Medical reported A$5.06M in cash and cash equivalents in its most recent financial results.

What is Nova Eye Medical’s dividend yield?

Nova Eye Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.